Novo Nordisk A/S
ISIN DK0062498333
|WKN A3EU6F
Market cap (in EUR)
259,038.11 m
Country
Denmark
Sector
Healthcare
Dividend yield
2.63%
Overview
Description
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.
Healthcare Biopharmaceuticals System-Specific Biopharmaceuticals Denmark
Financials
Key metrics
| Market capitalisation, EUR | 259,038.11 m |
| EPS, EUR | 3.15 |
| P/B ratio | 13.88 |
| P/E ratio | 18.43 |
| Dividend yield | 2.63% |
Income statement (2024)
| Revenue, EUR | 38,945.31 m |
| Net income, EUR | 13,543.28 m |
| Profit margin | 34.78% |
What ETF is Novo Nordisk A/S in?
There are 334 ETFs which contain Novo Nordisk A/S. All of these ETFs are listed in the table below. The ETF with the largest weighting of Novo Nordisk A/S is the Xtrackers MSCI Nordic UCITS ETF 1D.
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH.
Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.
Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.
